These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6938997)

  • 1. An inverse correlation between serum levels of desmethylimipramine and melatonin-like immunoreactivity in DMI-responsive depressives.
    Halbreich U; Weinberg U; Stewart J; Klein DF; Weitzman ED; Quitkin FM
    Psychiatry Res; 1981 Feb; 4(1):109-13. PubMed ID: 6938997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients.
    Palazidou E; Papadopoulos A; Ratcliff H; Dawling S; Checkley SA
    Psychol Med; 1992 May; 22(2):309-15. PubMed ID: 1319597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of desipramine in endogenomorphically depressed patients.
    Stewart JW; Quitkin F; Fyer A; Rifkin A; McGrath P; Liebowitz M; Rosnick L; Klein DF
    J Affect Disord; 1980 Sep; 2(3):165-76. PubMed ID: 6210722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma MHPG in depression: effects of acute and chronic desipramine treatment.
    Charney DS; Heninger GR; Sternberg DE; Roth RH
    Psychiatry Res; 1981 Oct; 5(2):217-29. PubMed ID: 6945615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between tricyclic antidepressant plasma levels and clinical response in patients treated with desipramine or doxepin.
    Brunswick DJ; Amsterdam JD; Potter L; Caroff S; Rickels K
    Acta Psychiatr Scand; 1983 Jun; 67(6):371-7. PubMed ID: 6880821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocturnal serum melatonin in major depressive disorder before and after desmethylimipramine treatment.
    Brown RP; Caroff S; Kocsis JH; Amsterdam J; Winokur A; Stokes P; Frazer A
    Psychopharmacol Bull; 1985; 21(3):579-81. PubMed ID: 4041061
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical implications of 2-hydroxydesipramine plasma concentrations.
    Nelson JC; Bock JL; Jatlow PI
    Clin Pharmacol Ther; 1983 Feb; 33(2):183-9. PubMed ID: 6822031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output.
    Kennedy SH; Brown GM
    Psychiatry Res; 1992 Aug; 43(2):177-85. PubMed ID: 1410073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Hydroxydesipramine and desipramine plasma levels: how are they related to antidepressant response?
    Stern SL; Cooper TB; Nelson LD; Johnson MH; Suckow RF
    Int Clin Psychopharmacol; 1996 Dec; 11(4):219-27. PubMed ID: 9031987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects.
    Thompson C; Mezey G; Corn T; Franey C; English J; Arendt J; Checkley SA
    Br J Psychiatry; 1985 Oct; 147():389-93. PubMed ID: 4075027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant activity of 2-hydroxydesipramine.
    Nelson JC; Mazure C; Jatlow PI
    Clin Pharmacol Ther; 1988 Sep; 44(3):283-8. PubMed ID: 3416551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of imipramine (IMI) and desmethylimipramine (DMI) and clinical response in prepubertal major depressive disorder: a preliminary report.
    Puig-Antich J; Perel JM; Lupatkin W; Chambers WJ; Shea C; Tabrizi MA; Stiller RL
    J Am Acad Child Psychiatry; 1979; 18(4):616-27. PubMed ID: 541469
    [No Abstract]   [Full Text] [Related]  

  • 13. Imipramine blood levels and clinical outcome.
    Rigal JG; Albin HC; Duchier AR; D'Aulnay JM; Fenelon JH; Vincon GA; Demotes-Mainard FM
    J Clin Psychopharmacol; 1987 Aug; 7(4):222-9. PubMed ID: 3624505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylimipramine treatment.
    Pariante CM; Miller AH
    Eur Neuropsychopharmacol; 1995; 5 Suppl():83-8. PubMed ID: 8775764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible nonlinear pharmacokinetics of desipramine after once daily dosing.
    Amsterdam JD; Brunswick DJ; Potter L; Rickels K
    Pharmacopsychiatry; 1986 Mar; 19(2):84-7. PubMed ID: 3703927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
    Cooke RG; Warsh JJ; Stancer HC; Reed KL; Persad E
    Clin Pharmacol Ther; 1984 Sep; 36(3):343-9. PubMed ID: 6467794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission.
    Cowen PJ; Green AR; Grahame-Smith DG; Braddock LE
    Br J Clin Pharmacol; 1985 Jun; 19(6):799-805. PubMed ID: 2992560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data.
    Brunswick DJ; Amsterdam JD; Mendels J; Stern SL
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 1):605-10. PubMed ID: 436362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of melatonin rhythms in depression.
    Frazer A; Brown R; Kocsis J; Caroff S; Amsterdam J; Winokur A; Sweeney J; Stokes P
    J Neural Transm Suppl; 1986; 21():269-90. PubMed ID: 3462336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic effects of desmethylimipramine treatment on platelet serotonin uptake in depressed patients: a comparison with imipramine.
    Rausch JL; Moeller FG
    Psychiatry Res; 1991 Mar; 36(3):299-305. PubMed ID: 2062971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.